Fig. 2From: Blinatumomab: a bispecific T cell engager (BiTE) antibody against CD19/CD3 for refractory acute lymphoid leukemiaMechanism of action for blinatumomab as the first-in-class bispecific T cell engager (BiTE). One arm of blinatumomab binds to CD3, the other binds to CD19. This engages the unstimulated T cells which destroy the CD19+ cellsBack to article page